Protalix BioTherapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Protalix BioTherapeutics stock has a target of 15, which predicts an increase of 474.71% from the current stock price of 2.61.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$15	$15	$15	$15
Change	+474.71%	+474.71%	+474.71%	+474.71%

* Price targets were last updated on Feb 3, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Protalix BioTherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $10 → $15	Strong Buy	Maintains	$10 → $15	+474.71%	Feb 3, 2025
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $10	Strong Buy	Reiterates	$10	+283.14%	Nov 14, 2023
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $7 → $10	Strong Buy	Maintains	$7 → $10	+283.14%	Oct 31, 2023
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $11 → $7	Strong Buy	Maintains	$11 → $7	+168.20%	May 3, 2021
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $3 → $11	Strong Buy	Maintains	$3 → $11	+321.46%	Jun 8, 2020

More Analyst Ratings

Financial Forecast

Revenue This Year

89.27M

from 53.40M

67.17%

from 53.40M

Revenue Next Year

138.64M

from 89.27M

55.31%

from 89.27M

EPS This Year

0.31

from 0.04

754.23%

from 0.04

EPS Next Year

0.85

from 0.31

170.97%

from 0.31

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	62.90M	38.35M	47.64M	65.49M	53.40M	89.27M	138.64M
Revenue Growth	15.00%	-39.03%	24.22%	37.48%	-18.47%	67.17%	55.31%
EPS	-0.22	-0.62	-0.31	0.09	0.04	0.31	0.85
EPS Growth	-	-	-	-	-57.71%	754.23%	170.97%
Forward PE	-	-	-	-	-	8.34	3.08
No. Analysts	-	-	-	-	-	3	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	98.7M	144.1M
Avg	89.3M	138.6M
Low	81.1M	134.5M

Revenue Growth

Revenue Growth	2025	2026
High	84.8%	61.5%
Avg	67.2%	55.3%
Low	51.9%	50.7%

EPS Forecast

EPS	2025	2026
High	0.45	0.88
Avg	0.31	0.85
Low	0.19	0.82

EPS Growth

EPS Growth	2025	2026
High	1,131.8%	181.7%
Avg	754.2%	171.0%
Low	408.0%	162.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.